Literature DB >> 27536702

Construction of a Novel DNA Vaccine Candidate Encoding an HspX-PPE44-EsxV Fusion Antigen of Mycobacterium tuberculosis.

Bagher Moradi1, Mojtaba Sankian2, Yousef Amini2, Zahra Meshkat1.   

Abstract

BACKGROUND: Mycobacterium tuberculosis is the causative agent of tuberculosis (TB). Bacille Calmette-Guerin (BCG) vaccine, is not effective in adults, therefore, many efforts have been made to produce an effective adult TB vaccine. The aim of this study was to develop a new tuberculosis DNA vaccine candidate encoding a recombinant HspX-PPE44-EsxV fusion antigen of M. tuberculosis.
METHODS: A fusion DNA segment consisting of HspX, linker, PPE44, linker, and EsxV, after codon optimization, was designed. The fusion DNA was cloned and its sequence confirmed. Then, expression of a recombinant pcDNA3.1 (+)/HspX-PPE44-EsxV plasmid in Chinese hamster ovary (CHO) cells was verified by RT-PCR and Western-blot analysis.
RESULTS: A 1968 bp band in RT-PCR and a 68 kDa band on Western-blot analysis confirmed transcription and expression of recombinant hspX-ppe44-esxV in eukaryotic cells.
CONCLUSION: A recombinant DNA segment encoding the HspX-PPE44-EsxV fusion antigen of M. tuberculosis was constructed and considered to be tested as a new TB DNA vaccine candidate.

Entities:  

Keywords:  DNA vaccine; EsX; Hsp; Mycobacterium tuberculosis; PPE44

Year:  2016        PMID: 27536702      PMCID: PMC4986267     

Source DB:  PubMed          Journal:  Rep Biochem Mol Biol        ISSN: 2322-3480


  29 in total

Review 1.  Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae.

Authors:  Tom H M Ottenhoff; Frank A W Verreck; Elgin G R Lichtenauer-Kaligis; Marieke A Hoeve; Ozden Sanal; Jaap T van Dissel
Journal:  Nat Genet       Date:  2002-09       Impact factor: 38.330

Review 2.  Current status of TB vaccines.

Authors:  Umesh Datta Gupta; Vishwa Mohan Katoch; David N McMurray
Journal:  Vaccine       Date:  2007-02-16       Impact factor: 3.641

3.  Therapy of tuberculosis in mice by DNA vaccination.

Authors:  D B Lowrie; R E Tascon; V L Bonato; V M Lima; L H Faccioli; E Stavropoulos; M J Colston; R G Hewinson; K Moelling; C L Silva
Journal:  Nature       Date:  1999-07-15       Impact factor: 49.962

Review 4.  Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis.

Authors:  A S Mustafa
Journal:  Curr Pharm Biotechnol       Date:  2001-06       Impact factor: 2.837

Review 5.  Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae.

Authors:  Esther van de Vosse; Marieke A Hoeve; Tom H M Ottenhoff
Journal:  Lancet Infect Dis       Date:  2004-12       Impact factor: 25.071

6.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.

Authors:  B Bourdin Trunz; Pem Fine; C Dye
Journal:  Lancet       Date:  2006-04-08       Impact factor: 79.321

7.  A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10).

Authors:  Fransois-Xavier Berthet; Peter Birk Rasmussen; Ida Rosenkrands; Peter Andersen; Brigitte Gicquel
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

Review 8.  Tuberculosis vaccine research: the impact of immunology.

Authors:  Lewellys F Barker; Michael J Brennan; Peri K Rosenstein; Jerald C Sadoff
Journal:  Curr Opin Immunol       Date:  2009-06-07       Impact factor: 7.486

9.  Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains.

Authors:  R D Fleischmann; D Alland; J A Eisen; L Carpenter; O White; J Peterson; R DeBoy; R Dodson; M Gwinn; D Haft; E Hickey; J F Kolonay; W C Nelson; L A Umayam; M Ermolaeva; S L Salzberg; A Delcher; T Utterback; J Weidman; H Khouri; J Gill; A Mikula; W Bishai; W R Jacobs; J C Venter; C M Fraser
Journal:  J Bacteriol       Date:  2002-10       Impact factor: 3.490

10.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  5 in total

1.  Immunological Assessment of Chitosan or Trimethyl Chitosan-Coated PLGA Nanospheres Containing Fusion Antigen as the Novel Vaccine Candidates Against Tuberculosis.

Authors:  Sirwan Zare; Mona Kabiri; Yousef Amini; Adel Najafi; Fatemeh Mohammadpour; Seyed Hasan Ayati; Amin Reza Nikpoor; Mohsen Tafaghodi
Journal:  AAPS PharmSciTech       Date:  2021-12-10       Impact factor: 3.246

Review 2.  Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines.

Authors:  Azar Valizadeh; Abbas Ali Imani Fooladi; Hamid Sedighian; Mahdieh Mahboobi; Elaheh Gholami Parizad; Elham Behzadi; Afra Khosravi
Journal:  Curr Microbiol       Date:  2022-07-19       Impact factor: 2.343

3.  A new DNA vaccine expressing HspX-PPE44-EsxV fusion antigens of Mycobacterium tuberculosis induced strong immune responses.

Authors:  Bagher Moradi; Mojtaba Sankian; Yousef Amini; Aida Gholoobi; Zahra Meshkat
Journal:  Iran J Basic Med Sci       Date:  2020-07       Impact factor: 2.699

4.  Evaluation of Triple Fragment Vaccine HSPX (Rv2031c) + PPE44 (Rv2770c) + Mouse IgG1 (Fcγ2a) with Auxiliary Adjuncts IL-22 in Comparison with BCG Vaccine.

Authors:  Azar Valizadeh; Afra Khosravi; Hamid Sedighian; Elham Behzadi; Elaheh Gholami Parizad; Abbas Ali Imani Fooladi
Journal:  Iran J Pathol       Date:  2022-08-13

Review 5.  Nanoparticle Vaccines Against Infectious Diseases.

Authors:  Rashmirekha Pati; Maxim Shevtsov; Avinash Sonawane
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.